Emerging Therapies Using Appetite-Neutral Muscle-Preserving Agents for Obesity Management

Abstract

Obesity remains a formidable public health challenge, with traditional weight management strategies often complicated by loss of lean body mass and unwanted appetite modulation. Recently, appetite-neutral muscle-preserving agents have emerged as a promising therapeutic class, offering the potential for effective fat mass reduction while maintaining skeletal muscle integrity. This review synthesizes current evidence on the epidemiology, pathophysiology, and clinical presentation of obesity, before focusing on the mechanistic rationale, efficacy, and clinical utility of these innovative therapies. We discuss their place in emerging guidelines and highlight practical considerations for clinicians managing patients with obesity.

Introduction

Obesity is a chronic, multifactorial disease associated with significant morbidity, mortality, and healthcare costs globally. While caloric restriction and pharmacological agents have achieved varying degrees of success, loss of skeletal muscle and compensatory increases in appetite remain key limitations. Muscle-preserving, appetite-neutral pharmacotherapies represent a paradigm shift, targeting adiposity while preserving or enhancing muscle mass, thereby potentially improving metabolic outcomes and physical function. This review provides a comprehensive overview of the scientific rationale and clinical implications of these emerging agents.

Epidemiology / Disease Burden

Obesity now affects over 650 million adults worldwide, with prevalence rates continuing to climb in both developed and developing nations. The World Health Organization (WHO) recognizes obesity as a global epidemic, contributing substantially to the burden of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, certain cancers, and musculoskeletal disorders. The economic impact is profound, with direct and indirect healthcare costs consuming a significant proportion of healthcare budgets. Importantly, traditional therapies often fail to achieve sustained weight loss or preserve muscle mass, underscoring the urgent need for innovative strategies.

Pathophysiology

Obesity results from a complex interplay of genetic, environmental, behavioral, and metabolic factors. Central to its pathophysiology is an imbalance between energy intake and expenditure, often compounded by dysregulated neurohormonal signaling. Adipose tissue expansion is characterized by both hypertrophy and hyperplasia of adipocytes, leading to chronic low-grade inflammation, insulin resistance, and impaired metabolic flexibility. Loss of skeletal muscle, either through disuse or as a consequence of weight loss interventions, exacerbates metabolic derangements and impairs physical function. Mechanism-based therapies aim to selectively reduce fat mass without detrimental effects on muscle tissue.

Risk Factors

Major risk factors for obesity include genetic predisposition, sedentary lifestyle, high-calorie diets, sleep disturbances, certain medications, and psychosocial stressors. Age, ethnicity, and socioeconomic status also play contributory roles. Importantly, weight loss strategies that do not account for muscle preservation can worsen sarcopenic obesity in older adults, further increasing the risk of frailty and metabolic complications.

Clinical Features

Obesity is clinically defined as a body mass index (BMI) ≥30 kg/m². Patients may present with central adiposity, increased waist circumference, and comorbid conditions such as hypertension, dyslipidemia, and impaired glucose tolerance. Physical examination may reveal decreased muscle strength and endurance, particularly in cases where prior weight loss has led to significant lean mass depletion. Recognition of these features is critical for tailoring therapy and monitoring treatment response.

Diagnosis

Diagnosis is based on anthropometric measurements, including BMI and waist circumference, alongside comprehensive assessment of comorbidities and metabolic status. Dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis provide valuable insights into body composition, enabling differentiation between fat mass and lean mass changes. Laboratory evaluation should include fasting glucose, HbA1c, lipid profile, liver enzymes, and assessment for secondary causes of obesity.

Treatment & Management

Current management strategies encompass lifestyle modification, pharmacotherapy, and bariatric surgery. Behavioral interventions focus on dietary caloric restriction and increased physical activity, but often result in compensatory appetite increases and unintended muscle loss. Pharmacotherapies such as GLP-1 receptor agonists and SGLT-2 inhibitors, while effective for weight loss, may not adequately preserve muscle mass. Bariatric surgery is reserved for severe obesity but carries risks of nutritional deficiencies and muscle wasting.

Recent Advances / Emerging Therapies

Appetite-neutral muscle-preserving agents are emerging as a novel class, distinguished by their unique mechanism of action. These agents, including selective androgen receptor modulators (SARMs), myostatin inhibitors, and activin receptor antagonists, preferentially target adipose tissue while maintaining or enhancing skeletal muscle mass. Preclinical and early-phase clinical trials demonstrate promising efficacy in reducing fat mass with minimal impact on appetite and lean tissue. For example, bimagrumab, a monoclonal antibody targeting activin type II receptors, has shown significant fat mass reduction and muscle preservation in adults with obesity. Myostatin inhibition, by blocking negative regulators of muscle growth, further supports muscle anabolism during weight loss. Importantly, these agents may improve physical function, metabolic health, and long-term weight maintenance, addressing key limitations of current therapies. Ongoing trials are evaluating their safety, efficacy, and long-term outcomes in diverse patient populations.

Guideline Recommendations

Contemporary guidelines from organizations such as the Endocrine Society and Obesity Medicine Association emphasize individualized, multidisciplinary care. While appetite-neutral muscle-preserving agents are not yet universally recommended, their inclusion in future guidelines is anticipated as robust evidence accumulates. Clinicians should remain apprised of evolving data, assess patient eligibility carefully, and consider these agents in individuals at high risk of muscle loss or with sarcopenic obesity, pending regulatory approval.

Conclusion

The advent of appetite-neutral muscle-preserving agents marks a significant advancement in obesity pharmacotherapy, with the potential to transform clinical practice by targeting fat reduction without compromising muscle integrity. These emerging therapies hold promise for improving metabolic health, physical function, and sustained weight management outcomes. Further large-scale, long-term studies are required to establish their safety, efficacy, and optimal place in therapy. Ongoing research and guideline updates will inform their integration into evidence-based obesity care.